Inside Insilico Medicine's $2.5 Billion AI Drug Alliance with Bora Pharmaceuticals

How the Alliance Weaves Together Two Platforms

Insilico's contribution centers on its proprietary Pharma.AI platform, which spans target discovery (PandaOmics), generative chemistry (Chemistry42), and molecule optimization. Insilico brings a track record of nominating 31 preclinical candidates since 2021, with an average discovery-to-candidate timeline of 12–18 months .

Bora's contribution covers global expertise in formulation, CMC (chemistry, manufacturing and controls), regulatory development, scale-up, quality systems, commercial manufacturing, supply chain execution, and commercialization .

The shared vision aims to link AI-enabled discovery with automation-driven development, manufacturing, and quality execution. Insilico will also support Bora in strengthening AI capabilities across its global workforce and apply AI to improve efficiency across manufacturing, supply chain, distribution, and corporate operations .

What the CEOs Said About the Deal

• Bobby Sheng, founder, Chairman of Bora Group, and CEO of Bora Pharmaceuticals, said: "This strategic alliance marks an important step in Bora's evolution from a leading pharmaceutical development and manufacturing partner into a broader drug innovation ecosystem… This is not simply about adding AI to existing processes; it is about reimagining how pharmaceutical products are developed, manufactured, and brought to patients."
• Dr. Alex Zhavoronkov, founder, co-CEO, and CBO of Insilico Medicine, said: "Building on our collaborations with Takeda and SK Biopharmaceuticals in Asia-Pacific, this alliance with Bora further demonstrates Insilico's commitment to partnering with leading biopharmaceutical innovators across the region… Together with Bora, we aim to connect that discovery engine with the capabilities required to advance high-quality drug candidates through development, manufacturing, and potential commercialization."

Recent Financial and Pipeline Milestones Since the Hong Kong IPO

Insilico Medicine listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025 (HKEX: 3696), raising HKD 2.277 billion in what became the largest biotech IPO in Hong Kong for 2025, with backing from investors including Eli Lilly and Tencent . The IPO brought cash and bank balances to US$393.3 million as of December 31, 2025 .

2025 Annual Results (filed March 2026):

• Total revenue of US$56.24 million, with software revenue from the Pharma.AI platform growing 23.8% year-over-year and subscription customers increasing 18.3% .
• The platform now serves 13 of the top 20 global pharmaceutical companies .

Pipeline expansion:

• Nominated 6 new preclinical candidates in 2025 (bringing the total to 28 nominated PCCs to date), including ISM3830 (CBLB inhibitor for oncology), ISM0676 (GIPR antagonist for obesity), ISM5059 (NLRP3 inhibitor for inflammation), and ISM6166 (pan-KRAS inhibitor) .
• 10 programs now in clinical trials, including 2 Phase II programs, 4 Phase I programs, and 2 IND milestones .
• ISM001-055 (Rentosertib), an AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis, achieved the first clinical proof-of-concept for an AI-discovered drug, with Phase IIa results published in Nature Medicine .

Major partnerships:

• In June 2026, Insilico announced a record $2.5 billion R&D collaboration with SK Biopharmaceuticals to develop neuroimmune therapies for CNS diseases .
• In July 2026, it issued a positive profit alert for the first half of 2026, expected to reduce net loss by over 50% versus the prior-year period, driven by expanded milestone payments and partnerships with firms including Tigermed, JOINN Laboratories, and Ribo Life Science .